Fotivda (Tivozanib)
- Medicine Name: Fotivda
- Generic Name: Tivozanib
- Dosage Form & Strength: Capsules: 1.34 mg and 0.89 mg
- Manufactured By: AVEO Pharmaceuticals, Inc.
Fotivda is a kinase inhibitor used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
Recommended Dosage: The recommended dosage is 1.34 mg taken orally once daily for 21 days on treatment followed by 7 days off treatment for a 28-day cycle. Continue treatment until the disease is progressive or until unacceptable toxicity occurs.
Take Fotivda capsules with or without food. Swallow the full capsule with water. Avoid opening the capsule. In case a dose is missed, the next scheduled dose should be taken at the next scheduled time. Avoid taking a couple of doses at the same time
- Tivozanib can cause severe hypertension and hypertensive crises. Control blood pressure prior to initiating treatment. Monitor blood pressure after 14 days and at least monthly thereafter during treatment with Tivozanib.
- Discontinue Tivozanib if hypertension is severe and persistent despite anti-hypertensive therapy and dose reduction of Tivozanib, or in patients who experience hypertensive crisis. If Tivozanib is interrupted, assess patients taking anti-hypertensive medicines for hypotension.
- Fotivda (Tivozanib Capsules) can be responsible for causing severe, sometimes fatal, cardiac failure. Periodically monitor patients for signs and symptoms of cardiac failure throughout therapy with Fotivda.
- Tivozanib can cause severe, sometimes fatal, events of cardiac ischemia and arterial thromboembolic. Precisely assess patients who are at risk for, or who have a known history of these events (such as myocardial infarction and stroke), during therapy with Tivozanib.
- Fotivda therapy can cause severe, sometimes fatal, venous thromboembolic events. Precisely assess patients who are at risk for, or who have a known history of these events during treatment. Discontinue treatment in patients who develop any severe or life-threatening events of venous thromboembolic.
- Treatment with Fotivda 1.34 mg Capsules can cause severe, sometimes fatal, hemorrhagic events. Watchfully monitor patients who are at risk for or who have a known history of bleeding during therapy with Fotivda. Discontinue therapy in such patients who develop severe or life-threatening hemorrhagic events.
- Tivozanib therapy can cause proteinuria. Assess patients for proteinuria before initiation of, and periodically throughout, therapy with Tivozanib. For patients who develop moderate to severe proteinuria, reduce the dose or interrupt therapy.
- Impaired wound healing may occur in patients who receive medicines that inhibit the VEGF signaling pathway, such as Tivozanib. Avoid using or administering this medicine for at least 14 days (2 weeks) following major surgery and until adequate wound healing.
- Treatment with Tivozanib 1.34 mg Capsules can cause thyroid dysfunction. Monitor thyroid function prior to initiating, and periodically throughout, Tivozanib treatment. Hyperthyroidism and hypothyroidism needs to be treated to maintain euthyroid state prior to and during treatment with Tivozanib.
- Mechanism of action suggests that this medicinal product can cause fetal harm if administered to a pregnant woman. Both males and females of reproductive potential should use appropriate contraception during treatment with Tivozanib and for 30 days after the final dose.
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients Identity Proof (issued by Govt of India)
- Valid prescription of Doctor
- Import permit if applicable
- On availability of Fotivda in India (Ahmedabad, Mumbai, Kolkata, Hyderabad, Chennai, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
Indian Pharma Network is able to source the FOTIVDA (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Fotivda®?
Tivozanib is Generic Name for the trade name drug Fotivda®.
What is the Manufacturer Name of Fotivda®?
Fotivda® is manufactured by AVEO Pharmaceuticals, Inc.
Is Fotivda® approved by the FDA?
Yes, Fotivda® is approved by the FDA. Date of approval: March 10, 2021.
What is Fotivda®?
Fotivda contains Tivozanib, which is an oral, once-daily, differentiated vascular endothelial growth factor receptor TKI approved by the FDA to treat adult patients with renal cell carcinoma (RCC).
What is the dosage and form of Fotivda® supplied?
Fotivda® is supplied as Capsules: 1.34 mg and 0.89 mg for oral administration.
What are the most common side effects due to Fotivda®?
Most common side effects due to Fotivda® include: cough, fatigue, hypertension, decreased appetite, nausea, diarrhea, dysphonia, hypothyroidism, and stomatitis.
How much does Fotivda® cost in India?
The fotivda cost in India is absolutely reasonable. In order to procure this RCC medication authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Fotivda®?
Store the Capsules of Fotivda at 20 to 25°C (68 to 77°F); excursions permitted between 15 to 30°C (59 to 86°F). Keep the medicine out of reach of children.
Is it safe to buy Fotivda® online?
Yes, In order to buy Fotivda Capsules in India, always look for an authentic, legitimate, WHO-GDP and ISO certified Pharmaceutical Wholesaler/Distributor/Supplier.
What are the Highlights of prescribing information for Fotivda®?
Click Here to download full fotivda prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.